Brenzavvy vs Farxiga for T2D; PFAS in Seafood; 100 Deaths Linked to GLP-1 Drugs?
(MedPage Today) -- Bexagliflozin (Brenzavvy) and dapagliflozin (Farxiga) induced similar HbA1c reductions over 24 weeks in a head-to-head phase III trial of the SGLT2 inhibitors in Chinese adults with type 2 diabetes on metformin. (Journal of Diabetes... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 16, 2024 Category: Endocrinology Source Type: news
Increased Retinopathy Risk Seen With GLP-1RAs for Diabetes Increased Retinopathy Risk Seen With GLP-1RAs for Diabetes
But diabetes-related eye complication risks were reduced with SGLT2 inhibitors and insulin.Medscape News UK (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - April 16, 2024 Category: Primary Care Tags: Internal Medicine Clinical Summary Source Type: news
EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI
Empagliflozin added to standard care did not improve outcomes in post-MI patients at risk for heart failure. John Mandrola, MD, sees the diminishing returns for add-on drugs as positive for patients.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 12, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
SGLT2 Inhibitors Reduce Anemia Risk in Concomitant T2D, CKD SGLT2 Inhibitors Reduce Anemia Risk in Concomitant T2D, CKD
Initiating treatment with SGLT2 inhibitors vs GLP-1 RAs was linked to a 19% reduced risk for composite anemia outcomes in patients with T2D and CKD stages I-III.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 11, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news
Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor
(MedPage Today) -- ATLANTA -- The SGLT2 inhibitor empagliflozin (Jardiance) did not exactly prevent deaths and heart failure (HF) events when initiated atop other standard therapies for acute myocardial infarction (MI), the EMPACT-HF trial found... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
SGLT2 Inhibitors Safe for HF in Congenital Heart Disease SGLT2 Inhibitors Safe for HF in Congenital Heart Disease
SGLT2 inhibitors not only were safe in adult patients with congenital heart disease who develop heart failure but also were associated with reduced hospitalizations.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 5, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Diabetes Drugs Overpriced; Hormone Drugs and Brain Tumors; Menopause or Herpes?
(MedPage Today) -- Insulins, SGLT2 inhibitors, and GLP-1 receptor agonists can likely be manufactured for prices "far below" their current prices, according to an economic evaluation of manufacturing costs in JAMA Network Open.
In related news... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 2, 2024 Category: Endocrinology Source Type: news
Gaps Found in Appropriate SGLT2, GLP-1 Prescribing Gaps Found in Appropriate SGLT2, GLP-1 Prescribing
A trio of new studies showed that SGLT2 inhibitors and GLP-1 agonists are often not prescribed or accessible to people who could benefit from them.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 21, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Is SGLT2 Inhibitor-Associated Ketoacidosis Treated With Enough Insulin?
(MedPage Today) -- Patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) received significantly lower doses of insulin in the first 24 hours of treatment compared with patients with type 1 diabetes DKA, according to a retrospective... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 19, 2024 Category: Cardiology Source Type: news
Oral SGLT2 Inhibitors Reverse MASLD in Diabetes Oral SGLT2 Inhibitors Reverse MASLD in Diabetes
Among oral antidiabetic drugs, SGLT2 inhibitors were linked to better liver outcomes in patients with both diabetes and MASLD in a new study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 7, 2024 Category: Consumer Health News Tags: Diabetes & Endocrinology Source Type: news
GLP-1 Agonists and SGLT2 Inhibitors Do Not Increase Autoimmune Risk GLP-1 Agonists and SGLT2 Inhibitors Do Not Increase Autoimmune Risk
Patients with type 2 diabetes prescribed GLP-1 receptor agonists or SGLT2 inhibitors did not have a greater risk of developing autoimmune disease than those prescribed DPP-4 inhibitors.Medscape Medical News (Source: Medscape Nurses Headlines)
Source: Medscape Nurses Headlines - March 4, 2024 Category: Nursing Tags: Rheumatology Source Type: news
SGLT2 Inhibitors: Cause of False-Positive Test Results? SGLT2 Inhibitors: Cause of False-Positive Test Results?
A case raises the suggestion that sugars in the urine are fermented due to failure to keep the samples refrigerated.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 26, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news
SGLT2 Inhibitors Tied to Better NAFLD Outcomes vs Other Antidiabetic Agents
(MedPage Today) -- In adults with both type 2 diabetes and nonalcoholic fatty liver disease (NAFLD), the use of SGLT2 inhibitors was linked to NAFLD regression and a lower incidence of poor liver-related outcomes, according to a retrospective cohort... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 14, 2024 Category: Primary Care Source Type: news
SGLT2 Inhibitors Reduce Kidney Stone Risk in Type 2 Diabetes SGLT2 Inhibitors Reduce Kidney Stone Risk in Type 2 Diabetes
Patients with type 2 diabetes treated with SGLT2 inhibitors vs other common diabetes drugs show up to a 31% reduced risk of kidney stone development.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 6, 2024 Category: Endocrinology Tags: Diabetes & Endocrinology Source Type: news
One Class of Antidiabetic Linked With Lower Kidney Stone Risk
(MedPage Today) -- One class of glucose-lowering agent may help lower the risk of kidney stones in adults with type 2 diabetes, a cohort study suggested.
Adults who newly started on an SGLT2 inhibitor had a 31% lower risk of nephrolithiasis compared... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 29, 2024 Category: Cardiology Source Type: news
